Teladoc Health Inc. Watch

from 10-Q 18 pages 1. Separation. as of the Date Hereof, We Hereby Acknowledge Your Intent to Resign on the Close of Business on December 31, 2024 (The “Separation Date”), With Great Thanks for Your Valuable Contributions to the Company to Date. You and the Company Agree That You Intend to Continue to Be Employed and Will Provide Agreed Upon Reasonable Transition Services to the Company Through the Separation Date (The “Transition Period”). During the Transition Period, You May Engage in Outside Business Activities With Non-Competitive Entities So Long as They Do Not Materially Interfere With the Performance of Your Duties or Pose a Conflict of Interest; Provided That for So Long as You Remain Employed by the Company You Shall Be Subject to the Company’s Code of Business Conduct and Ethics, Related-Party Transaction Policy and Other Relevant Policies, as Reasonably Administered by the Company in a Manner Consistent With Past Practice, and Provided, Further That During the Transition Period, the Company Shall Not Object to You Joining the Board of Any Portfolio Company of Morningside Technology Advisory, LLC. on the Separation Date, Your Employment With the Company Will Terminate in All Capacities and You Will Cease to Serve the Company as Its Chief Operating Officer. You and the Company Will Mutually Agree on All Internal and External Announcements Regarding Your Departure. 2. Base Salary and Benefits Through and After the Separation Date

from 10-Q 7 pages Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan Performance Restricted Stock Unit Grant Notice

from 10-Q 5 pages Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan Restricted Stock Unit Grant Notice

from 8-K 1 page First Amendment to Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan

from 8-K 4 pages Amendment No. 2 to Executive Severance Agreement

from 8-K 13 pages Employment Agreement

from 8-K 26 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions

from 10-Q 4 pages Amendment No. 2 to Executive Severance Agreement

from 10-Q 5 pages Retention Bonus Agreement

from 10-Q 12 pages April 11, 2024 Jason Gorevic via E-Mail Re: Release and Separation Agreement Dear Jason

from 10-Q 2 pages April 1, 2024 Mala Murthy via E-Mail Re: Interim CEO Duties and Responsibilities

from 10-K 6 pages Amendment No. 1 to Executive Severance Agreement

from 10-K 12 pages Executive Severance Agreement

from 10-K 12 pages Executive Severance Agreement

from 10-K 14 pages December 1, 2023 Claus Jensen [ ] Re: Separation and Release of Claims Agreement Dear Claus: As We Have Discussed, Your Employment With Teladoc Health, Inc. (The “Company”) as Chief Innovation Officer Will Terminate Effective as of December 1, 2023 (“Termination Date”)

from 10-K 3 pages Teladoc Health, Inc. Non-Employee Director Compensation Program

from 10-Q 5 pages Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan Performance Restricted Stock Unit Grant Notice

from 10-Q 5 pages Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan Restricted Stock Unit Grant Notice

from 10-Q 5 pages Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan Restricted Stock Grant Notice

from 10-Q 4 pages Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan Stock Option Grant Notice